Pliant Therapeutics, Inc. (PLRX)
- Previous Close
12.86 - Open
12.81 - Bid 12.11 x 100
- Ask 12.22 x 400
- Day's Range
12.01 - 12.87 - 52 Week Range
12.00 - 30.85 - Volume
342,731 - Avg. Volume
369,567 - Market Cap (intraday)
734.316M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-2.75 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.54
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
pliantrx.comRecent News: PLRX
Performance Overview: PLRX
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLRX
Valuation Measures
Market Cap
734.32M
Enterprise Value
251.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
453.03
Price/Book (mrq)
1.55
Enterprise Value/Revenue
159.14
Enterprise Value/EBITDA
-1.59
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.68%
Return on Equity (ttm)
-41.01%
Revenue (ttm)
1.58M
Net Income Avi to Common (ttm)
-161.34M
Diluted EPS (ttm)
-2.75
Balance Sheet and Cash Flow
Total Cash (mrq)
494.24M
Total Debt/Equity (mrq)
2.40%
Levered Free Cash Flow (ttm)
-66.86M
Research Analysis: PLRX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell